カテゴリ： GlobalData, アメリカ, 企業調査

Aeterna Zentaris Inc (AEZS)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aeterna Zentaris Inc (AEZS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10022
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of endocrine disorders. The company’s lead product, macimorelin, a ghrelin receptor agonist and orally-active small molecule that stimulates the secretion of growth hormone intended for the diagnosis of adult growth hormone deficiency (AGHD). Aeterna Zentaris has licensed macimorelin to Strongbridge Biopharma plc, to develop, manufacture, register and commercialize in the US and Canada. Some of the other pipeline products of the company include Zoptrex. Aeterna Zentaris is headquartered in Summerville, South Carolina, the US.

Aeterna Zentaris Inc (AEZS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Aeterna Zentaris Enters into Agreement with EMD Serono 14
Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15
Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16
Licensing Agreements 17
Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17
Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18
Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19
Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20
Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23
Equity Offering 24
Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24
Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25
Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26
Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28
Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For US$50 Million 30
Aeterna Zentaris Completes Public Offering Of Units For US$13.2 Million 31
AEterna Zentaris Completes Public Offering Of Units For US$15 Million 32
AEterna Zentaris Completes Private Placement Of Units For US$7.8 Million 34
AEterna Zentaris Announces Public Offering Of Shares For US$4.6 Million 35
Aeterna Zentaris Completes Public Offering Of Units For US$17 Million 36
Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For US$2 Million 37
Aeterna Zentaris Inc – Key Competitors 38
Aeterna Zentaris Inc – Key Employees 39
Aeterna Zentaris Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Nov 06, 2018: Aeterna Zentaris reports third quarter 2018 financial and operating results 41
Aug 09, 2018: Aeterna Zentaris reports second quarter 2018 financial and operating results 42
May 07, 2018: Aeterna Zentaris Reports First Quarter 2018 Financial and Operating Results 43
Mar 28, 2018: Aeterna Zentaris Announces Fourth Quarter And Full-Year 2017 Financial Results 45
Nov 08, 2017: Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results 48
Aug 10, 2017: Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results 50
May 08, 2017: Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results 53
Mar 15, 2017: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results 55
Corporate Communications 57
Sep 25, 2018: Aeterna Zentaris names Leslie Auld as Chief Financial Officer 57
Mar 05, 2018: Aeterna Zentaris Names James Clavijo As Chief Financial Officer 58
Dec 08, 2017: Aeterna Zentaris Announces Departure of Interim Chief Financial Officer 59
Sep 25, 2017: Aeterna Zentaris Announces Appointment of Interim Chief Financial Officer 60
Sep 01, 2017: Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer 61
Legal and Regulatory 62
Dec 22, 2017: Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore 62
Dec 21, 2017: David Dodd and Philip Theodore respond to claim by Aeterna Zentaris 63
Product News 64
12/20/2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency 64
03/05/2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit 65
Product Approvals 66
Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency 66
Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date 67
Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults 68
Mar 30, 2017: Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017 69
Mar 07, 2017: Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen 70
Clinical Trials 71
May 01, 2017: Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex Did Not Achieve its Primary Endpoint 71
Apr 28, 2017: Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex 72
Mar 02, 2017: Aeterna Zentaris Announces Presentation Regarding Macrilen at 99th Annual Meeting of the Endocrine Society 73
Feb 14, 2017: Aeterna Zentaris Announces Zoptrex Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium 74
Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen 75
Jan 30, 2017: Aeterna Zentaris Announces Completion of Zoptrex Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017 77
Jan 04, 2017: Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen 78
Other Significant Developments 79
May 08, 2018: Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeterna Zentaris Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Aeterna Zentaris Enters into Agreement with EMD Serono 14
Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15
Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16
Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17
Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18
Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19
Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20
Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21
Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22
Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23
Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24
Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25
Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26
Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28
Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For US$50 Million 30
Aeterna Zentaris Completes Public Offering Of Units For US$13.2 Million 31
AEterna Zentaris Completes Public Offering Of Units For US$15 Million 32
AEterna Zentaris Completes Private Placement Of Units For US$7.8 Million 34
AEterna Zentaris Announces Public Offering Of Shares For US$4.6 Million 35
Aeterna Zentaris Completes Public Offering Of Units For US$17 Million 36
Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For US$2 Million 37
Aeterna Zentaris Inc, Key Competitors 38
Aeterna Zentaris Inc, Key Employees 39
Aeterna Zentaris Inc, Subsidiaries 40

List of Figures
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Aeterna Zentaris Inc (AEZS)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Telia Co (TELIA)：企業の財務・戦略的SWOT分析
    Telia Co (TELIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • SDX Energy Inc (SDX)：石油・ガス：M&Aディール及び事業提携情報
    Summary SDX Energy Inc (SDX), formerly Sea Dragon Energy Inc., is an independent upstream company. It carries out the exploration, development and production of crude oil and natural gas liquids. The company’s primary areas of focus are Morocco and Egypt. Its principal operations are currently conce …
  • Nichi-Iko Pharmaceutical Co Ltd (4541)：企業の財務・戦略的SWOT分析
    Summary Nichi-Iko Pharmaceutical Co Ltd (Nichi-Iko) is a manufacturer of generic products. The company eripheral nervous system medicines. The company offers products such as alacepril tablets, aluminum hydroxide gel, aranidipine capsules, bacampicillin hydrochloride tablets, barium sulfate, betahis …
  • Nissin Foods Holdings Co Ltd (2897)：企業の財務・戦略的SWOT分析
    Nissin Foods Holdings Co Ltd (2897) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Critical Outcome Technologies Inc (COT)-製薬・医療分野：企業M&A・提携分析
    Summary Critical Outcome Technologies Inc (COTI) is a biopharmaceutical company that develops targeted therapeutics with focus on oncology. The company’s lead program COTI-2 is a novel small molecule activator of misfolded mutant p53 proteins for the treatment of ovarian and other gynecological canc …
  • Energy Fuels Inc (EFR)：企業の財務・戦略的SWOT分析
    Energy Fuels Inc (EFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Advanced Accelerator Applications SA (AAAP)-製薬・医療分野：企業M&A・提携分析
    Summary Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment o …
  • Territorial Generating Company #2 (TGKB)：企業の財務・戦略的SWOT分析
    Territorial Generating Company #2 (TGKB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • ReShape Medical Inc：医療機器：M&Aディール及び事業提携情報
    Summary ReShape Medical Inc (ReShape Medical), a subsidiary of EnteroMedics Inc is a medical device company that offers weight loss solutions. The company provides dual intragastric balloon for weight loss. Its product comprises of ReShape Duo, a non surgical dual-intragastric balloon used in the tr …
  • Qualicaps Inc：企業の戦略的SWOT分析
    Qualicaps Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Eagle Energy Inc (EGL)：石油・ガス：M&Aディール及び事業提携情報
    Summary Eagle Energy Inc (Eagle) is an oil and gas company that acquires for, develops and produces oil and gas reserves through its subsidiaries. It focuses on the acquisition and exploitation of conventional long-life hydrocarbon reserves in on-shore production basins in North America. It acquires …
  • Airasia Group Berhad：企業の戦略・SWOT・財務分析
    Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report Summary Airasia Group Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Pharmstandard：企業の戦略的SWOT分析
    Pharmstandard - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Altius Minerals Corp：企業の戦略・SWOT・財務情報
    Altius Minerals Corp - Strategy, SWOT and Corporate Finance Report Summary Altius Minerals Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • ARK Diagnostics Inc：企業の製品パイプライン分析
    Summary ARK Diagnostics Inc (ARK Diagnostics) is a developer, manufacturer and commercializer of in vitro diagnostic immunoassay products. The company's products include protease inhibitors, levetiracetam assay, topiramate assay, non-nucleoside reverse transcriptase inhibitors, gabapentin assay, lam …
  • Harley-Davidson, Inc.：企業の戦略・SWOT・財務情報
    Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report Summary Harley-Davidson, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • The Goldman Sachs Group Inc (GS)：企業の財務・戦略的SWOT分析
    The Goldman Sachs Group Inc (GS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Trilliant Holdings, Inc.：企業の戦略的SWOT分析
    Trilliant Holdings, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Enusa Industrias Avanzadas SA SME：企業の戦略的SWOT分析
    Enusa Industrias Avanzadas SA SME - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Salzgitter AG：企業の戦略・SWOT・財務分析
    Salzgitter AG - Strategy, SWOT and Corporate Finance Report Summary Salzgitter AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆